BioPharmSignal logoBioPharmSignal

Biotech News

Arvinas to Participate in Upcoming Investor Conferences

Arvinas, Inc. (ARVN)Arvinas, Inc.Company update

NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual

Related news

ARVNArvinas, Inc.2026-03-11 11:00 EST

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

ARVNArvinas, Inc.2026-03-18 11:00 EST

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

INVAInnoviva2026-06-01 15:00 EST

Innoviva to Participate in Upcoming Investor Conferences

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

NRIXNurix Therapeutics2026-05-13 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

KYMRKymera2026-05-06 11:00 EST

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

CCCCC4 Therapeutics2026-05-20 11:00 EST

C4 Therapeutics to Participate in Upcoming Conferences

PHARPharming Group2026-04-07 06:00 EST

Pharming Group to participate in April investor conferences

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

EXELExelixis2026-05-07 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-06-04 12:00 EST

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

ARVNArvinas, Inc.2026-05-29 20:01 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 14:30 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 11:05 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-12 11:00 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Stock data

Close
10.78 USD
Market cap
695.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States